Policy breakthrough: out-of-pocket influenza vaccines may now be covered by medical insurance, potentially boosting vaccination willingness and creating a stimulative effect.

① The policy may directly boost vaccination willingness, particularly exerting a positive pull effect among working populations and elderly individuals and children covered under family mutual aid schemes; ② Given the current industry supply-demand dynamics, the prevailing low-price competition in the influenza vaccine market is unlikely to reverse in the short term. However, as vaccine manufacturers continue public education campaigns that raise public awareness and vaccination intent—combined with steadily expanding payment channels for vaccines—the industry’s operating conditions are expected to gradually stabilize.

cls.cnMay 19 21:20

Q&A with the Company | Baik Biotech: The company's R&D projects do not include a Hantavirus vaccine.

Gelonghui, May 18th | An investor asked Baik Biotech on an interactive platform: Has your company started research on the Hantavirus and development of related vaccines? Baik Biotech replied that its ongoing research projects do not include a Hantavirus vaccine. For information on the company’s R&D projects, please refer to the company’s regular reports and relevant interim announcements, as disclosures are made in accordance with applicable regulations.

Gelonghui FinanceMay 18 14:51

Company Q&A | Baik Biotech: The company's varicella vaccine product is a non-immunization program vaccine at the national level, but it has been included in local immunization programs in some provinces and cities.

Gelonghui, May 9th | An investor asked Baik Biological on an interactive platform: Is the company's varicella vaccine included in medical insurance? Baik Biological replied that its varicella vaccine product is categorized as a non-immunization program vaccine at the national level. Currently, the product has been incorporated into the local immunization programs in some provinces and cities. The company focuses on systematically advancing market initiatives through terminal coverage expansion, channel optimization, and academic promotion. It continuously deepens and consolidates penetration in grassroots medical institutions and vaccination sites while adopting multiple measures to enhance the coverage of its products.

Gelonghui FinanceMay 9 16:07

Baike Biotech reported revenue of 605 million yuan in 2025, a year-on-year decrease of 50.77%, with a net loss attributable to shareholders of 263 million yuan.

Both gross profit margin and net profit margin are under pressure, with the core business suffering from a severe lack of self-sustaining capabilities.

lanjinger.comApr 22 11:08

2025 Annual Report of Changchun Beacon Biotechnology Co., Ltd.

SZSIApr 22 00:00 · Announcements

First Quarter Report of Changchun Beacon Biotechnology Co., Ltd. for 2026

SZSIApr 22 00:00 · Announcements